Johnson & Johnson (J&J) and its subsidiaries are engaged in the research, development, manufacture and sales of pharmaceuticals, medical devices and consumer health products. The company recorded sales of USD 70.07 billion, a decrease by 5.7% compared to increases of 4.2% in 2014 and 6.1% in 2013. This can be attributed to increased competition in the infectious disease segment and the impact of acquisitions and divestitures on global operations. The earnings per share in 2015 was USD 5.56. The total pharmaceuticals sales in 2015 was USD 31.4 billion accounting for 44.9% of the total sales. The pharmaceutical sales of the company in 2015 declined by 2.7% (compared to 2014) due to operational decrease and negative currency impact along with increased competition to the Hepatitis C products (OLYSIO/SOVRIAD and INCIVO) in the U.S.
In 2016, J&J stood at USD 53.8 billion, total increase of 2.9%, as compared to 2015 fiscal nine months sales of $52.3 billion. The fiscal third quarter (Q3) sales were USD 17.8 billion an increase of 4.2% compared to 2015 Q3 sales with earnings per share at USD 1.56. The company recorded a total pharmaceutical sales of fiscal nine months at USD 25.2 billion in 2016 which is 8% higher as compared to the same period in 2015, mainly due to operational growth, market growth of oncology products in Asia-Pacific region and positive currency impact. Q3 pharmaceutical sales stood at USD 8.4 billion an increase of 9.2% as compared to the same period a year ago. Contributors to the growth were strong sales of IMBRUVICA and DARZALEX (oncology segment) along with new launches of DARZALEX in Europe and ZYTIGA in China